# Pelacarsen Roll-over Extension Program

Study · id `cardio:ct-nct06875973` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06875973](<https://clinicaltrials.gov/study/NCT06875973>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06875973

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 599 participants.

## Technical summary

Registry record NCT06875973. Allocation not applicable; no masking; primary purpose treatment. Start 2025-05-19 (actual); primary completion 2030-12-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 599 participants (planned count; ClinicalTrials.gov record NCT06875973, source copy `cardio:ctgov-nct06875973-2026-10-14`, retrieved 2026-10-31)
- Started: 2025-05-19 (actual) (ClinicalTrials.gov record NCT06875973, source copy `cardio:ctgov-nct06875973-2026-10-14`, retrieved 2026-10-31)
- Primary completion: 2030-12-08 (anticipated) (ClinicalTrials.gov record NCT06875973, source copy `cardio:ctgov-nct06875973-2026-10-14`, retrieved 2026-10-31)
- Completion: 2030-12-08 (anticipated) (ClinicalTrials.gov record NCT06875973, source copy `cardio:ctgov-nct06875973-2026-10-14`, retrieved 2026-10-31)
- Countries: United States; Puerto Rico (ClinicalTrials.gov record NCT06875973, source copy `cardio:ctgov-nct06875973-2026-10-14`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06875973-2026-10-14`, retrieved 2026-10-31)

## The registry's words

- Brief title: Pelacarsen Roll-over Extension Program
- Condition: Atherosclerotic Cardiovascular Disease
- Intervention (Drug): Pelacarsen (TQJ230)
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 1d05c704d12db076f7d428c3bcc5ab1043d1e2abcefa962d7657edd59459d880
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
